Livanova News - Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
The S5 HLM, by LivaNova The Most Successful HeartLung Machine Ever
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
LivaNova receives FDA clearance for extracorporeal membrane oxygenation
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
LivaNova, PLC Announces the First U.S. Implants of Perceval, the Only
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
March 10 2023
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
LivaNova to Unveil New Data Further Demonstrating the Perceval
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
LivaNova Initiates Targeted Commercial Launch Of The Essenz Patient
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
Virtual ACC LivaNova highlights Vitaria data
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
How LivaNova developed a nextgeneration perfusion system Medical
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
COVID19 LivaNova can modify indications of its cardiopulmonary
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
LivaNova to Present Autonomic Regulation Therapy Findings for Heart
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.
Web this performance notably exceeds analyst expectations, which estimated revenue at $278.66 million.